Oncopharmpod
TILs, Olutasidenib, T-DXd
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:17:52
- More information
Informações:
Synopsis
Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.
